IL10 and neoplasm: Moreover, in the current cohort, IL-10 secretion at baseline was predictive of tumor burden after six cycles of 223Ra therapy, indicating that performing an IL-10 ELISpot prior to treatment may help to decide if this therapy should really be applied, especially in patients with numerous comorbidities.